3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
4
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
19
Ovarian Neoplasms
12
Fallopian Tube Neoplasms
9
Stomach Neoplasms
4
Vulvar Neoplasms
3
Vaginal Neoplasms
2
Peritoneal Neoplasms
2
Mesothelioma, Malignant
2
Carcinoma, Ovarian Epithelial
2
Brenner Tumor
2
Vomiting
1
Uterine Neoplasms
1
Triple Negative Breast Neoplasms
1
Sertoli-Leydig Cell Tumor
1
Sarcoma
1
Rhabdomyosarcoma
1
Recurrent Uterine Corpus Carcinoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Penile Neoplasms
1
Pelvic Neoplasms
1
Ovarian gynandroblastoma
1
Neoplasm Metastasis
1
Nausea
1
Lung Neoplasms
1
Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified
1
Locally Advanced Cervical Carcinoma
1
Locally Advanced Cervical Adenocarcinoma
1
Liposarcoma
1
HIV Infections
1
Interventions
pembrolizumab
14
Specimen Handling
8
Docetaxel
8
olaparib
7
Nivolumab
7
Gemcitabine
7
Trastuzumab
6
Paclitaxel
6
rucaparib
5
Magnetic Resonance Spectroscopy
5
Early Intervention, Educational
5
Biopsy
5
Standard of Care
4
Cyclophosphamide
4
Carboplatin
4
tisotumab vedotin
3
talazoparib
3
pertuzumab
3
durvalumab
3
atezolizumab
3
Taxes
3
Surveys and Questionnaires
3
Sirolimus
3
Radiotherapy
3
Psychiatric Rehabilitation
3
Methods
3
Irinotecan
3
Immunoglobulin G
3
Fulvestrant
3
Educational Status
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Platinum
×
Gynecologic
×
Clear all
NCT06769425
2025-06-24
HS-10502
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
Recruiting
157 enrolled